Not Signed In -
Clonidine |
Catapres |
Clinical Trial: Novel Medications for Opiate Detoxification - 4
This study has been completed.
Purpose
The purpose of this study is to evaluate novel medications for opiate detoxification.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Opioid-Related Disorders Substance-Related Disorders | Drug: Clonidine | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: Novel Medications for Opiate Detoxification
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Please contact site for information.
Location Information
Connecticut
VA Connecticut Healthcare System, New Haven, Connecticut, 06519, United States
Study chairs or principal investigators
Thomas R Kosten, M.D., Principal Investigator, VA Connecticut Healthcare System
More Information
Study ID Numbers: NIDA-09250-4; P50-09250-4
Record last reviewed: December 2002
Last Updated: November 18, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000279
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: December 2002
Last Updated: November 18, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000279
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
